COLON-TARGETED DRUG DELIVERY: UNRAVELLING THE INNOVATIONS AND CHALLENGES

Dhanshri Mahajan[1], Pranay Kurariya[2], Akash Yadav[3]*, Dinesh Kumar Jain[4]

Abstract:
Colonic diseases and disorders necessitate precise drug delivery strategies to optimize therapeutic outcomes while minimizing systemic side effects. This paper explores the multifaceted landscape of colon-specific drug delivery, elucidating various strategies employed to achieve targeted release. We delve into the intricate design principles of prodrugs, pH-responsive formulations, and stimuli-responsive nanocarriers, offering a critical evaluation of their merits and challenges. The efficient delivery of therapeutic agents to the colon has emerged as a pivotal challenge in pharmaceutical research, particularly in the context of treating localized gastrointestinal disorders and enhancing the efficacy of drugs with systemic applications. This review paper aims to provide a comprehensive overview of various colon-targeting strategies employed in drug delivery systems. We systematically analyze and synthesize the current state of knowledge regarding different approaches, including prodrugs, pH-sensitive systems, time-dependent release systems, and microbial-triggered delivery systems.

Key words: Colon Anatomy, Targeted Delivery Systems, Colonic Diseases, Targeted Drug Delivery, Colonic Microflora

[1,2,3*,4]IPS Academy College of Pharmacy, Knowledge Village, Rajendra Nagar, A.B. Road, Indore- 452012, India

***Corresponding Author:** Dr. Akash Yadav
*IPS Academy College of Pharmacy, Knowledge Village, Rajendra Nagar, A.B. Road, Indore- 452012, India
Email- akashyadav@ipsacademy.org

DOI: - 10.53555/ecb/2022.11.12.299

Introduction:

Solid oral dosage forms have historically been made to release their medication in the upper parts of the gastrointestinal track, where the environment is usually more favorable for drug dissolution and assimilation. Controlling the rate and/or site of medication release from oral formulations has received more attention recently in an effort to increase patient compliance and therapeutic effectiveness.[1] The gastrointestinal tract's colonic region is one area that would profit from the creation and application of such modified release technologies. Numerous conditions, such as ulcerative colitis, Crohn's disease, irritable bowel syndrome, and carcinomas, can affect the colon. Therefore, direct treatment at the illness site would be ensured, the dose rate would be lowered, and the systemic side effects would be minimized with targeted drug delivery to the colon. The colon can be used as a gateway for the introduction of medications into the systemic circulation in addition to local therapy.[2] For instance, substances like proteins and peptides that are poorly absorbed or broken down in the upper intestine might be better absorbed from the colon's more hospitable environment. Additionally, disorders including asthma, angina, and arthritis that are sensitive to circadian rhythms can benefit from chronotherapy through systemic absorption from the gut.[3] The gastrointestinal (GI) tract must be protected from a medication's release in the stomach and small intestine before it can be abruptly released into the colon for drug delivery to the colon to be successful.[4] Numerous methods have been put out for colon-targeted medication delivery; the majority of these make use of the GI tract's and the colon's four primary characteristics, which are as follows:(i) an estimate of the small intestine's transit time, (ii) various physiological conditions indistinct GI tract sections, (iii) the colon's bacterial enzyme's selectivity, and (iv) the colon being the focus of medication delivery systems using colon-specific targeting moieties.[5]

Advantages of Colon Targeting Drug Delivery System:

- ✓ The colon is a perfect place to provide medications to treat the disorders that are specific to the colon.
- ✓ One benefit of local treatment is that it uses less medication. lowers the frequency of dosing. Hence, less expensive of pricey medications.
- ✓ perhaps resulting in a lower frequency of negative effects impacts and medication interactions.[6]
- ✓ The colon is a desirable location where poorly absorbed medication molecules could have an enhanced bio availableness.
- ✓ lessen the gastrointestinal discomfort that many medications, like NSAIDS, produce.
- ✓ Initial first pass metabolism, good-bye.
- ✓ It seems to be very receptive to substances that improve the absorption of poorly absorbed medications and has a longer retention period.[7]

Limitations of Colon Targeting Drug Delivery System:

- ✓ Prior to absorption, the drug should be in solution; for poorly soluble medicines, this is the rate-limiting phase.
- ✓ Inability to find a suitable dissolve testing procedure for assessing the dosage form in vivo.[8]
- ✓ The unknown location and environment in which the coating may begin to breakdown is a significant drawback of the pH-sensitive coating technology. typical in individuals with colitis that ulcerates.
- ✓ One of the prodrug approach's limitations is that it is not a particularly adaptable method in terms of formulation based on the available functional group for chemical bonding on the medicinal moiety. Prodrugs are also novel chemical entities.[9]

Anatomy and Physiology of Colon:

The colon, which extends from the ileocecal junction to the anus, is the bottom portion of the gastrointestinal tract. The proximal portion (ascending colon) is included. Colons that are transverse, descending, sigmoid, rectum, and anus. As opposed to Despite the colon's small intestine's modest surface area, efficient absorption occurs because of microvilli, extended residence times, and villi. In the colon is a cylinder lined with soft, wet material mucosa, a pink lining that measures two to three inches in diameter. Anatomical features of the colon and rectum blood flow. Additionally, there are lymph nodes with blood arteries. There are two types of colonic activity segmenting and propulsive movements. Circular muscle-driven segmentation processes, which give rise to the sac-like haustra, are predominant and cause the luminal contents to mix. Significant propulsive action, mediated by longitudinal muscle and linked to defecation, is less frequent and averages thrice or thrice a day.[10]



Fig. 1: Anatomy of Colon

Colonic Microflora:

The colon's slow material flow promotes the growth of a sizable microbial population. More than 400 different types of bacteria have been located. The majority of the microorganisms that have been identified are anaerobic. A tiny percentage of fungi are also currently. The fastest pace of microbiological development due to the large concentration of energy sources in the nearby locations. The primary origin of Carbohydrates that enter the colonic canal provide nourishment for the colonic bacteria. Enzymes called polysaccharides and glycosidase break down the carbs, and the final fermentation products are short chain fat acids, with a predominance of carbohydrate fermentation producing a comparatively low pH. Within the Distal locations have a higher pH because there is less fermentation of carbohydrates there.[11]

Absorption of Drugs from the Colon:

Passive drug absorption occurs via paracellular or transcellular pathways. The majority of lipophilic medicines enter cells through a process known as transcellular absorption, whereas Transport of paracellular absorption entails the medication via the cell's tight connections Many medications have limited paracellular absorption in the colon because epithelial cells There are a lot of tight turns. The sluggishness of transit prolongs the time the medication is in contact with the mucosa of the colon compared to the small intestine. It makes up for the significantly reduced surface area. The viscosity of the intestinal material increases with increasing water uptake while moving farther into the colon. As a result, the medicine dissolves more slowly and at a slower pace. within the mucosa. This is how the majority of hydrophilic drugs travel.[12]

Colonic Diseases:

Inflammatory Bowel Disease:

Crohn's disease can strike any part of the digestive system, including the esophagus and the anus, although it most frequently affects the ileum. Multiple factors contribute to the development of inflammatory bowel disease, including aberrant immune responses and inflammation. response of the local immune system to the typical flora in the stomach, genetic elements like many genetic elements, potential genes, chromosomal position, Measles, cytomegalovirus, Escherichia coli, and other infectious pathogens; food components like dairy goods, foods containing saturated fats, allergies, etc. Ulcerative colitis and Crohn's disease are chronic conditions. Idiopathic inflammatory bowel disease (IBD) is the collective term for recurrent inflammatory disorders of unclear origin. Main medications utilized in the management of Crohn's disease and ulcerative colitis disease are corticosteroids and amino salicylates [26]. Along with other inflammatory bowel illnesses.[13]

Ulcerative Colitis:

All cases of ulcerative colitis are limited to the large intestine. The mucosa, or inner lining, of the colon or rectum is where ulcers originate. They frequently cause diarrhoea, blood, and shit. Usually, the inflammation is really severe in the rectum and sigmoid, and typically decreases in the colon.

Crohn's Disease:

Often limited to the ileum, the last segment of the small intestine, Crohn's disease, also known as localized enteritis, is a chronic intestinal inflammation.[14]

Irritable Bowel Syndrome:
The diagnosis of spastic colon or irritable bowel syndrome (IBS) is one of exclusion. It is a functional bowel illness that is typified by persistent abdominal bloating, pain, discomfort, and bowel changes routines in the lack of any discernible organic reason. An infection may be the cause of IBS, or a traumatic life experience. IBS is no known cure, yet there are therapies aimed at alleviating symptoms, including as pharmacological, nutritional, and behavioural therapies. A positive doctor-patient relationship and patient education are also crucial. IBS can be a symptom of a number of illnesses, such as giardiasis, celiac disease, fructose malabsorption, mild infections, a number of inflammatory bowel diseases, functional chronic constipation, and persistent functional abdominal pain. For IBS, standard clinical tests reveal no anomalies, although the intestines might be more susceptible to specific stimuli, like testing using balloon insufflation. The precise reason why There is no IBS. The prevalent hypothesis states that IBS is a condition involving the interplay of the gastrointestinal system and the brain, although abnormalities in the gut flora may also exist. [15]

Pseudomembranous Colitis:
Another name for pseudomembranous colitis is antibiotic-associated diarrhoea (AAD), which is a colon infection. It is frequently, though not always, brought on by the Clostridium difficile bacteria. The disease is characterized by fever, diarrhoea with an unpleasant odour, and stoma pain. In dire situations, Life-threatening issues may arise, including as a mega-colon poisonous.[16]

Overview of Colon-Related Diseases:
A variety of disorders affecting the large intestine are included in the category of colon-related diseases. Dietary variables, age, and family history all have an impact on colorectal cancer, a common and potentially fatal disease.[17] Chronic gastrointestinal inflammation is a feature of inflammatory bowel illnesses (IBD), which include Crohn's disease and ulcerative colitis. Symptoms of IBD include diarrhea and abdominal pain. A functional disease called irritable bowel syndrome (IBS) is characterized by discomfort in the abdomen and changes in bowel habits that are brought on by stress or certain meals. Diverticulitis, or inflammation of the colon pouches, is linked to a low-fiber diet and advanced age. Adenomatous polyps, which provide a risk of cancer, are among the abnormal growths on the colon lining known as colonic polyps. The symptoms of ischemic colitis, which are caused by decreased colon blood flow, include diarrhea with blood in it.[18] Vigilant screening is necessary because some hereditary disorders, such as Lynch syndrome and familial adenomatous polyposis (FAP), increase the risk of numerous colon polyps. The management of these disorders heavily relies on medical intervention, lifestyle changes, and early detection. Preventive care and early intervention techniques emphasize the significance of proactive actions to limit the impact of colon-related disorders on individual health. Regular screenings and consultations with healthcare providers are crucial components of these strategies.[19]

Importance of Targeted Drug Delivery to the Colon:
- ✓ **Precision Targeting:** Colonic drug administration provides a focused therapeutic approach for conditions including colorectal cancer and inflammatory bowel illnesses by precisely localizing drugs to the colon.
- ✓ **Minimized Systemic Exposure**: Medication administered directly to the colon greatly improves treatment safety by lowering the possibility of systemic exposure and possible negative effects in non-targeted organs.
- ✓ **Improved Efficacy:** Drug delivery to the colon is targeted, which maximizes therapeutic efficacy by guaranteeing that drugs reach their intended site of action and result in the intended clinical outcomes**.**
- ✓ **Enhanced Patient Compliance:** Colonic drug delivery systems, frequently featuring controlled or sustained release mechanisms, lessen the frequency of medicine administration, improving treatment adherence and patient compliance.
- ✓ **Reduction in Overall Drug Dosage:** By reducing the total dosage of drugs required, targeted drug delivery to the colon minimizes drug-related toxicity and enhances treatment safety.
- ✓ **Potential for Personalized Medicine:** The ability to tailor drug delivery to the colon offers a more personalized approach to treatment, considering the specific needs and conditions of individual patients, leading to more effective and precise therapeutic interventions.[20]

Approaches for Colonic Drug Delivery:
Drug release in the stomach and small intestine should be delayed by a colon-targeted drug delivery system (CTDDS), but full release of the drug should be permitted in the colon. Given that a system of any kind will be subject to a wide variety of gastrointestinal disorders during transit colonic

administration by mouth is difficult due of the gut statement.[21]

Table 1. Various Approaches for Colon Targeted Drug Delivery

Approach	Basic Feature
pH dependent systems	Enteric polymers, whose integrity is dependent on pH, cover the formulation and release the medicine as the pH approaches the alkaline side.[22]
Time dependent systems	Its foundation is the idea that a medicine should be released three to five hours after entering the small intestine.[23]
Pressure dependent systems	This method depends on the colon's potent peristaltic waves, which cause a brief rise in luminal pressure.[23]
Colon targeted microsponge	The method forms a tablet by compressing a microsponge that has been loaded with medication. Tablets with a combination of HPMC and pectin are coated to create colon focused delivery.[23]

Colon-Targeted Drug Delivery Systems:

PH-Dependent Systems:

Drug delivery systems that are reliant on pH are made to release medication in response to changes in the pH of the gastrointestinal tract. These methods aim to achieve targeted delivery to the colon by using pH thresholds to initiate medication release. Drug release is reduced in an acidic environment, like the stomach, preventing the medication from activating too soon. Drug release is started as soon as the system comes into contact with the colon's higher pH, maximizing therapeutic efficacy and reducing systemic exposure. Due to its ability to accurately transport medication to the targeted site of action, this technique shows promise in the treatment of disorders unique to the colon, such as inflammatory bowel diseases.[24]

Time-Dependent Systems:

Time-dependent drug delivery systems are essential to colon targeting because they regulate drug release according to preset temporal parameters. With these systems, medications are released gradually and continuously over a predetermined period of time, which corresponds to the length of time the gastrointestinal tract takes to pass. Drug transport to the colon is optimized by time-dependent systems, which use formulations that permit a regulated release. This is especially helpful for conditions involving the colon, like inflammatory bowel disorders, where it's critical to sustain a steady therapeutic dose over time. In the setting of problems peculiar to the colon, time-dependent systems provide predictability and sustained release, which promote therapy efficacy and patient adherence.[25]

Microbial-Triggered Systems:

In colon tareting, microbial-triggered drug delivery devices take advantage of the distinct microbial ecology of the colon to enable targeted drug release. These systems are made to react when certain types of colonic bacteria are present. These bacteria ferment indigestible materials and create metabolites. By adding these substrates to medication formulations, bacterial enzymatic activity causes microbial-triggered systems to become active in the colon, while remaining dormant in the upper gastrointestinal tract. By ensuring focused medication release in the colon, this method minimizes systemic exposure and maximizes therapeutic efficacy. These systems are especially useful for treating inflammatory bowel disorders and other colonic illnesses because they use the unique microbial makeup of the colon to deliver drugs to specific areas of the body.[26]

Combined Systems:

Multiple processes are integrated by combined drug delivery systems in colon targeting to improve the accuracy and efficacy of medication administration to the colon. To maximize drug release, these systems frequently incorporate elements of time-dependent, microbial-triggered, and pH-dependent systems. Through the integration of several triggers and responsive elements, including pH-sensitive coatings and microbially-activated components, these systems offer a multifaceted strategy to guarantee precise distribution. By providing a flexible approach that can adjust to the changing circumstances of the gastrointestinal system, this integration increases the likelihood of a medicine releasing successfully into the colon. Together, these mechanisms offer a holistic solution to improve therapeutic outcomes and make colon-specific disease treatment more dependable and flexible.[27]

Considerations in the Drug Delivery to Colon:

The targeting of colon drug delivery must take into account the variations in the physiology, anatomy, and structure of the gastrointestinal tract as well as the drug release site and dosage transit kinetics. Furthermore, important differences between the

two types of gastrointestinal tracts—the diseased and the healthy—should be taken into account. Only with a prior knowledge of the gastrointestinal tract's environment can dosage forms be evaluated more effectively both in vivo and in vitro. Consequently, it is necessary to talk about a few pathological and physiological aspects that are crucial to the formulation and administration of the medication to the colon system.[28]

Ph:

Several areas of the gastrointestinal tract have pH values ranging from 1 to 8. While the environment of the small intestine spans from an acidic to neutral pH range (5.9–7.8), the stomach is located in an acidic zone (1-3 pH).[29,30] This colonic pH is crucial because it initiates the delivery of certain medications to the colon. colon medication administration. By covering the medicine with a polymer like Eudragit S100, which is stable at this pH, this pH-dependent drug delivery can stop the drug from degrading in the acidic environment of the stomach.[31] however, among the primary problems with pH are the variations in intra- and inter-individual levels medication delivery that is reliant. Additionally, patients with colitis and Crohn's disease have lower intestinal pH values, raising doubts about the effectiveness of pH-dependent drug delivery.[32]

Colonic Microflora:

Human colons have more than 300 colons. These bacteria break down polysaccharides, which are necessary for their energy, using hydrolytic and reductive enzymes.[33] The special environment that the dose form and substance provide can be used to stimulate their behaviour. species of bacteria. Because bacterial enzymes convert polysaccharides and prodrugs like guar gum, chitosan, and pectin into drugs, it is more likely that these will be used in colon administration.[34] On the other hand, bacterial drug metabolism may result in toxicity or inactivity. Furthermore, medication, food, and illness can additionally cause the intestinal microbiota to fluctuate. These results show that these circumstances can change how drugs based on bacterial enzyme compositions release, therefore this should be considered taking into account when creating a medication delivery system tailored to the gastrointestinal system.[35]

Transit Time:

Delivery systems that rely on time use the gastrointestinal tract's transit time as a strategy for colon targeting.[36] In the colon and small intestine, the transit times are 6–70 hours and 2–6 hours, respectively. Colic patients have demonstrated a faster transit time than other patients. In the event that a patient has gastrointestinal disease, however, the formulation's transit time is shortened. Because the therapeutic drugs' exposure to the diseased areas is shortened, the transit time reduction may result in a decrease in their efficacy.[37]

Mucus Barrier:

Mucus is a hydrogel layer that is rich in mucin and glycoproteins. It prevents the gastrointestinal tract from absorbing the medications.[38] Human mucus is composed of three layers: the basal layer, the thinner layer, and the luminal layer, which range in thickness from 10 to 200 μm. [39] Mucus serves the fundamental functions of lubricating chyme and shielding epithelial cells from infections and mechanical damage. The mucous layer prevents the drug from having the desired therapeutic effect since the drug is adhered to the mucus's surface, which is only removed in faces. This restricts how long the medication is delivered to the place of action.[40]

Conclusion:

Colon-targeting drug delivery systems represent a transformative paradigm in pharmaceuticals, addressing the challenges of conventional methods and providing targeted solutions for colonic diseases. pH-dependent, time-dependent, and microbial-triggered systems offer precise drug release, optimizing therapeutic outcomes. The integration of these mechanisms in combined systems enhances targeting precision and therapeutic efficacy. Emerging technologies, including electrically-triggered, magnetic-responsive, and nanoparticle-based systems, promise further advancements, offering tailored approaches for colon-specific drug delivery. Clinical implications are profound, with reduced side effects, improved patient adherence, and enhanced treatment outcomes. However, challenges in regulatory standards and the need for a comprehensive understanding of patient perspectives underscore the ongoing evolution of these technologies. As research progresses, colon-targeted drug delivery continues to shape a promising future, contributing significantly to the advancement of personalized medicine and the optimization of gastrointestinal therapeutics.

Acknowledgement:

We would like to express our sincere gratitude to IPS Academy College of Pharmacy for providing access to resources and facilities that facilitated our above article.

References:

1. Sawant RR, Torchilin VP. Challenges in development of targeted colon therapeutics. The AAPS journal. 2012; 14:303-15.
2. Jaiswal M, Lanjhiyana SK. Current Overview on Colon Specific Drug Delivery. Current Overview on Colon Specific Drug Delivery. 2022:1-29.
3. Chavan-Patil M, Mishra B. Colon-specific drug delivery-An Overview. ACTA Pharmaceutica Sciencia. 2015;41(4).
4. Sinha VR, Kumria R. Microbially triggered drug delivery to the colon. European journal of pharmaceutical sciences. 2003;18(1):3-18.
5. Gumurdulu Y, Yapar Z, Canataroglu A, Serin E, Gumurdulu D, Kibar M, Çolakoglu S. Gastric emptying time and the effect of cisapride in cirrhotic patients with autonomic neuropathy. Journal of clinical gastroenterology. 2010 Feb 1;36(2):175-8.
6. Yang L, Chu JS, Fix JA. Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. International journal of pharmaceutics. 2002;1-5.
7. Rathod S, Ram A, Thiru G. Colon targeted pulsatile drug delivery: A review. Pharma info net. 2007;5(2):1-1.
8. Rathod S, Ram A, Thiru G. Colon targeted pulsatile drug delivery: A review. Pharma info net. 2007;5(2):1-1.
9. Tiwari G, Tiwari R, Wal P, Wal A, Rai AK. Primary and novel approaches for colon targeted drug delivery-A review. International Journal of Drug Delivery. 2010 Jan 1;2(1).
10. Pye G, Evans DF, Ledingham S, Hardcastle JD. Gastrointestinal intraluminal pH in normal subjects and those with colorectal adenoma or carcinoma. Gut.2003 Dec 1;31(12):1355-7.
11. Gupta A, Mittal A, Gupta AK. Colon targeted drug delivery systems–a review. Russian Journal of Biopharmaceuticals. 2011 Jul 27;3(4):3-13.
12. Sarasija S, Hota A. Colon-specific drug delivery systems. Indian journal of pharmaceutical sciences. 2000;62(1):1-8.
13. Jarbandhan S, van der Veer WM, Mulder CJ. Double-balloon endoscopy in the diagnosis and treatment of hemorrhage from retrovalvular angiodysplasias. J Gastrointestin Liver Dis. 2008 Sep 1;17(3):333-4.
14. Sarasija S, Hota A. Colon-specific drug delivery systems. Indian journal of pharmaceutical sciences. 2000;62(1):1-8.
15. Camilleri M, Mangel AW, Fehnel SE, Drossman DA, Mayer EA, Talley NJ. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clinical Gastroenterology and Hepatology. 2007 May 1;5(5):534-40.
16. Larson HE. Pseudomembranous colitis is an infection. Journal of Infection.2020:221-6.
17. Reddy RD, Malleswari K, Prasad G, Pavani G. Colon targeted drug delivery system: a review. International Journal of Pharmaceutical Sciences and Research. 2013:42-51.
18. Li J, Yang L, Ferguson SM, Hudson TJ, Watanabe S, Katsuma M, Fix JA. In vitro evaluation of dissolution behaviour for a colon-specific drug delivery system (CODES™) in multi-pH media using United States Pharmacopeia apparatus II and III. AAPS PharmSciTech. 2002:59-67.
19. Bakshi HA, Quinn GA, Aljabali AA, Hakkim FL, Farzand R, Nasef MM, Abuglela N, Ansari P, Mishra V, Serrano-Aroca Á, Tambuwala MM. Exploiting the metabolism of the gut microbiome as a vehicle for targeted drug delivery to the colon. Pharmaceuticals. 2021:1211-21.
20. Hua S, Marks E, Schneider JJ, Keely S. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Nanomedicine: nanotechnology, biology and medicine. 2015 Jul 1;11(5):1117-32.
21. Jaiswal M, Lanjhiyana SK. Current Overview on Colon Specific Drug Delivery. Current Overview on Colon Specific Drug Delivery. 2022 Nov 23:1-29.
22. Watts PJ, Lllum L. Colonic drug delivery. Drug development and industrial pharmacy. 2001 Jan 1;23(9):893-913.
23. Wilding IR, Davis SS, Bakhshaee M, Stevens HN, Sparrow RA, Brennan J. Gastrointestinal transit and systemic absorption of captopril from a pulsed-release formulation. Pharmaceutical research. 2011:654-7.
24. Sidramappa Chickpetty M, Baswaraj R, Sunil Kumar G. Development of novel combined time and pH-dependent based drug delivery systems for targeting 5-fluorouracil to the colon. Current drug delivery. 2011:566-74.
25. Gazzaniga A, Maroni A, Sangalli ME, Zema L. Time-controlled oral delivery systems for colon targeting. Expert Opinion on Drug Delivery. 2006:583-97.
26. Singh CK, Saxena S, Yadav M, Samson AL. A review on novel approaches for colon targeted drug delivery systems. Pharma Tutor. 2018:11-22.
27. Amidon S, Brown JE, Dave VS. Colon-targeted oral drug delivery systems: design trends and approaches. Aaps Pharmscitech. 2015:731-41.

28. Hua S, Marks E, Schneider JJ, Keely S. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Nanomedicine: nanotechnology, biology and medicine. 2015:1117-32.
29. Collnot EM, Ali H, Lehr CM. Nano-and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. Journal of Controlled Release. 2012:235-46.
30. Koziolek M, Grimm M, Becker D, Iordanov V, Zou H, Shimizu J, Wanke C, Garbacz G, Weitschies W. Investigation of pH and temperature profiles in the GI tract of fasted human subjects using the Intellicap® system. Journal of pharmaceutical sciences. 2015:2855-63.
31. Kim JH, Shin DH, Kim JS. Preparation, characterization, and pharmacokinetics of liposomal docetaxel for oral administration. Archives of pharmacal research. 2018:765-75.
32. Fallingborg J, Christensen LA, Jacobsen BA, Rasmussen SN. Very low intraluminal colonic pH in patients with active ulcerative colitis. Digestive diseases and sciences. 1993:93-99.
33. Williams BA, Grant LJ, Gidley MJ, Mikkelsen D. Gut fermentation of dietary fibres: physico-chemistry of plant cell walls and implications for health. International journal of molecular sciences. 2017;2203-11.
34. Zhang L, Sang Y, Feng J, Li Z, Zhao A. Polysaccharide-based micro/nanocarriers for oral colon-targeted drug delivery. Journal of drug targeting. 2016;579-89.
35. McConnell EL, Fadda HM, Basit AW. Gut instincts: explorations in intestinal physiology and drug delivery. International journal of pharmaceutics. 2008;213-26.
36. Steed KP, Hooper G, Monti N, Benedetti MS, Fornasini G, Wilding IR. The use of pharmacoscintigraphy to focus the development strategy for a novel 5-ASA colon targeting system ("TIME CLOCK®" system). Journal of controlled release. 1997;115-22.
37. Rao KA, Yazaki E, Evans DF, Carbon R. Objective evaluation of small bowel and colonic transit time using pH telemetry in athletes with gastrointestinal symptoms. British journal of sports medicine. 2004 Aug 1;482-7.
38. Johansson ME, Ambort D, Pelaseyed T, Schütte A, Gustafsson JK, Ermund A, Subramani DB, Holmén-Larsson JM, Thomsson KA, Bergström JH, van der Post S. Composition and functional role of the mucus layers in the intestine. Cellular and molecular life sciences. 2011;3635-41.
39. Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Advanced drug delivery reviews. 2009;158-71.
40. Ponchel G, Irache JM. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Advanced drug delivery reviews. 1998;191-219.